Hospira

Hospira
Share
Hospira is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to advance wellness by improving patient and caregiver safety while reducing healthcare costs. Hospira is the recognized leader in IV Clinical Integration, which further supports hospitals in reducing error potential, increasing efficiency and avoiding costs. Learn more at www.hospira.com.

Hospira

 •  August 27, 2015

-- Next-generation infusion system offers expanded drug library and EMR interoperability --
LAKE FOREST, Ill., Aug. 27, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the first installation of the Plum 360™ infusion system with Hospira MedNet™, at Shannon ...

Hospira

 •  August 25, 2015

LAKE FOREST, Ill., and KANSAS CITY, Mo., Aug. 25, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and Cerner (NASDAQ: CERN), a global leader in healthcare technology, today announced a commitment to advance the integration of I.V.-EMR technology. The expanded agreement ...

Hospira

 •  August 20, 2015

LAKE FOREST, Ill., Aug. 20, 2015 -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the successful implementation of interoperability between the company's Plum A+™ intravenous (I.V.) infusion devices with Hospira MedNet™ safety software and the electronic medical record (EMR) ...

Hospira

 •  August 13, 2015

LAKE FOREST, Illinois, Aug. 13, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP) applauds the UK's National Institute for Health and Clinical Excellence (NICE) for developing and issuing a new adoption resource to further support the introduction of biosimilar infliximab, including Hospira's Inflectra™, allowing patients greater access to these ...

Hospira

 •  May 20, 2015

WASHINGTON, May 20, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP) joined forces with the Alliance for Health Reform and Amgen to bring the U.S. Food and Drug Administration (FDA) and industry leaders together today to discuss the future of biosimilars in the United States. With the U.S. Congress focused intently on the discovery, development, and ...

Hospira

 •  May 13, 2015

LAKE FOREST, Ill., May 13, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer Inc. at a special meeting of stockholders held today, ...

Hospira

 •  May 1, 2015

LAKE FOREST, Ill., May 1, 2015 -- Hospira, Inc. (NYSE: HSP), is pleased that the U.S. Food and Drug Administration (FDA) has issued its final guidance documents on biosimilar products. This regulatory guidance represents an important milestone as we collectively work to improve patient access to safe, effective and more affordable biologic ...

Hospira

 •  February 10, 2015

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced ...

Hospira

 •  January 20, 2015

-- Plum 360™ System with Hospira MedNet™ expands drug library and wireless capabilities --
LAKE FOREST, Ill., Jan. 20, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug ...

Hospira

 •  January 11, 2015

Jan. 11, 2015 -- As a leading global provider of biosimilars, Hospira is pleased to have provided public comments in support of bringing biosimilar products to the market as a participant in the recent U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting -- in which the panel recommended FDA approval of the ...